

ASX: EIQ RELEASE

6 March 2025

INVESTOR WEBINAR

Sydney: AI and Medical Technology company Echo IQ ("the Company" or "Echo IQ") (ASX: EIQ) is pleased to advise that it will host an investor webinar at 11:00am AEDT on Thursday, 13 March 2025.

Chief Executive Officer, Mr Dustin Haines, will provide a progress update on the US commercialisation strategy for EchoSolv-AS over the first two months of CY2025 (refer ASX announcement: 5 March 2025), along with an outlook on the Company's clinical development pipeline and other opportunities.

The briefing will be followed by a Q&A session.

Questions can be submitted now to investors@echoig.ai or in written form during the webinar.

Anyone wishing to attend the webinar must register using the below link.

Webinar details

Date and time: 11:00am AEDT (8:00am AWST) on Thursday, 13 March 2025

Register at: https://us02web.zoom.us/webinar/register/WN_FwV0VdnlTaCFsHZeRq4VBg#/registration

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Investor Enquiries: Andrew Grover, Executive Chair Andrew.grover@echoiq.ai / investor@echoiq.ai

Henry Jordan, Six Degrees Investor Relations <u>Henry.jordan@sdir.com.au</u> / +61 (0) 431 271 538

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.



ECHO IQ Limited ABN: 48 142 901 353 +61 2 9159 3719 / www.echoiq.ai 2.114 / 477 Pitt Street, Sydney NSW 2000 Australia